Results 1 to 10 of about 2,569,584 (209)

Quizartinib for Newly Diagnosed <i>FLT3</i>-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study. [PDF]

J Clin Oncol
PURPOSE Quizartinib, an oral, selective, second-generation, type-II FMS-like tyrosine kinase 3 (FLT3) inhibitor with high binding affinity to internal tandem duplication (ITD) and wild-type (WT) FLT3, has shown early clinical activity as monotherapy in ...
Montesinos P, Rodríguez-Veiga R, Bergua JM, Algarra Algarra JL, Botella C, Rodríguez-Arbolí E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, López-López JA, Vives S, López-Lorenzo JL, Colorado M, Vidriales MB, García Boyero R, Olave MT, Herrera Puente P, Arce O, Barrios M, Jose Sayas M, Polo M, Gómez-Roncero MI, Barragán E, Ayala R, Chillón C, Calasanz MJ, Paiva B, Boluda B, Casas-Avilés I, Lloret-Madrid P, Sánchez MJ, Rodríguez-Medina C, Cuevas L, Raposo-Puglia JÁ, Mateos MC, Olivares M, Martínez-Chamorro C, Alonso N, Suárez S, Sánchez-Vadillo I, Solé Rodríguez M, González BJ, Martínez-Francés A, Cuello R, Fernández A, Martínez-Cuadrón D, Labrador J, PETHEMA group, PETHEMA Group.   +51 more
europepmc   +2 more sources

Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial. [PDF]

Am J Hematol
ABSTRACT Quizartinib is a tyrosine kinase inhibitor with single agent activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and has demonstrated efficacy in first‐line therapy when combined with intensive chemotherapy in both FLT3 ITD‐negative and positive AML.
Bernal T, Zambrano Márquez J, Rodríguez-Veiga R, Rodríguez-Arbolí E, Bergua-Burgués JM, Vives S, Arnán M, Martínez Sánchez P, Herrera-Puente P, Serrano-López J, Rubio V, Marchante-Cepillo I, Cervera-Calvo M, Novo García A, Fernández Martín R, Gil Cortés C, Rodríguez-Medina C, Noriega-Concepción V, Alfonso-Piérola A, Loredo C, Antuña-Casal M, Boluda B, Cano-Ferri I, Acuña-Cruz E, Torres-Miñana L, Sánchez-García J, Bilbao C, Gómez-Casares MT, Martínez Cuadrón D, Montesinos P.   +29 more
europepmc   +2 more sources

Experimental Investigation of the Influence of Wire Arc Additive Manufacturing on the Machinability of Titanium Parts

Metals, 2019
The manufacturing of titanium airframe parts involves significant machining and low buy-to-fly ratios. Production costs could be greatly reduced by the combination of an additive manufacturing (AM) process followed by a finishing machining operation ...
Unai Alonso, Fernando Veiga, Alfredo Suárez, Teresa Artaza   +3 more
doaj   +2 more sources

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study. [PDF]

Am J Hematol
ABSTRACT The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3‐mutated acute myeloid leukemia (AML); however, real‐world data in elderly patients (≥ 60 years) are limited. This large, retrospective, multicenter study from three European registries (PETHEMA, FILO, DATAML) evaluated MIDO+IC (n ...
Aspas Requena G, Montesinos P, Bérard E, Bertoli S, Rodríguez-Veiga R, Simand C, Torres L, Peterlin P, Tormo M, Birsen R, Bergua-Burgues JM, Tavernier E, Bernal Del Castillo T, Carré M, Gil C, Contejean A, Rodríguez-Arbolí E, Orvain C, Rodríguez-Medina C, Veronese L, Sayas Lloris MJ, Delabesse E, Serrano J, Mineur A, García-Fortes M, Guieze R, Amigo ML, Pigneux A, Algarra Algarra L, Recher C, Dumas PY, Martínez-Cuadrón D.   +31 more
europepmc   +2 more sources

Bovine Colostrum-Derived Extracellular Vesicles Impair Cancer Cell Proliferation Through Transcriptional Dysregulation. [PDF]

J Extracell Vesicles
ABSTRACT Milk‐derived extracellular vesicles (EVs) are a promising source of molecules with therapeutic potential. Bovine colostrum is particularly enriched in EVs, which carry cargo of proteins involved in immune regulation, development and cellular signalling.
Huesa-Carballo CB, Puga B, Bravo S, Rodríguez-Pérez M, Domínguez-Novoa Y, Iglesias-García J, Hermida B, Raña I, Antelo MT, López-López R, Abal M, Barbazán J.   +11 more
europepmc   +2 more sources

Discriminative features for Alzheimer disease based on peripheral blood deep‐immunophenotyping [PDF]

Alzheimers Dement
Abstract Background Immunity is a key driving factor in pathogenesis and progression of Alzheimer's disease. Here we examine the peripheral changes in both innate and adaptive immunity in AD and healthy subjects between 50 and 80 years old by immunophenotyping and systems immunology.
Feng Y, Veiga R, Yshii L, Neumann J, Prezzemolo T, Pasciuto E, Humblet‐Baron S, Liston A, Vandenberghe R.   +8 more
europepmc   +2 more sources

Model for the Prediction of Deformations in the Manufacture of Thin-Walled Parts by Wire Arc Additive Manufacturing Technology

Metals, 2021
Gas Metal Arc Welding (GMAW) is a manufacturing technology included within the different Wire Arc Additive Manufacturing alternatives. These technologies have been generating great attention among scientists in recent decades.
Mikel Casuso, Fernando Veiga, Alfredo Suárez, Trunal Bhujangrao, Eider Aldalur, Teresa Artaza, Jaime Amondarain, Aitzol Lamikiz   +7 more
doaj   +2 more sources

A systems immunology analysis of Alzheimer's disease reveals an age- and environmental exposure-independent disturbance in B cell maturation. [PDF]

Alzheimers Dement
Abstract INTRODUCTION Alzheimer's disease is a severe neurodegenerative disorder, with multifactorial mechanisms of disease development and progression. Evidence from genetic association studies, animal models, and clinical investigation suggests a neuroimmunological component to disease, with links to the peripheral immune system.
Humblet-Baron S, Feng Y, Veiga R, Neumann J, Prezzemolo T, Pasciuto E, Vandenberghe R, Yshii L, Liston A.   +8 more
europepmc   +2 more sources

Abdominal splenosis mimicking peritoneal carcinomatosis of ovarian cancer [PDF]

Radiology Case Reports, 2023
We present the clinical case of a 53-year-old woman referred for suspicion of recurrence of a mesonephric-like adenocarcinoma of the ovary. Abdominal and pelvic CT revealed multiple round/oval solid nodules with similar density scattered throughout the ...
Filipe Barros Alves, MD, Diogo M. Rombo, MD, Vera Veiga, MD, Paulo Santos Correia, MD, Lucília Salgado, MD, Teresa Margarida Cunha, MD   +5 more
doaj   +2 more sources

A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX. [PDF]

Cancer
Abstract Background LAMVYX was a multicenter, single‐arm, phase 2 trial designed to validate the safety and efficacy of CPX‐351 in patients aged 60–75 years with newly diagnosed, secondary acute myeloid leukemia and to generate evidence on key issues not addressed in the preceding regulatory pivotal trial. Methods The primary end point of the study was
Rodríguez-Arbolí E, Rodríguez-Veiga R, Soria-Saldise E, Bergua JM, Caballero-Velázquez T, Arnán M, Vives S, Serrano J, Bernal T, Martínez-Sánchez P, Tormo M, Rodríguez-Medina C, Herrera-Puente P, Lavilla-Rubira E, Boluda B, Acuña-Cruz E, Cano I, Cáceres S, Ballesteros J, Falantes J, Martínez-Cuadrón D, Pérez-Simón JA, Montesinos P, PETHEMA Group.   +23 more
europepmc   +2 more sources